Fig. 1: Impact of changes in the risk of vaccine SAEs or severe outcomes following infection on the number of cases averted across different epidemiological scenarios (rows), assuming 50% or 95% vaccine efficacy (columns). | Nature Health

Fig. 1: Impact of changes in the risk of vaccine SAEs or severe outcomes following infection on the number of cases averted across different epidemiological scenarios (rows), assuming 50% or 95% vaccine efficacy (columns).

From: A framework for risk–benefit analysis of vaccines approved through accelerated pathways

Fig. 1: Impact of changes in the risk of vaccine SAEs or severe outcomes following infection on the number of cases averted across different epidemiological scenarios (rows), assuming 50% or 95% vaccine efficacy (columns).The alternative text for this image may have been generated using AI.

Positive and negative cases averted (per 10,000 in each age group) are coloured in orange and pink, respectively. The dashed diagonal line indicates the threshold of zero net benefit. The risks associated with chikungunya infection and vaccination for each age group (per 10,000) are denoted by the shapes.

Back to article page